CDK4 and sarcoma: The present review demonstrated that a CDK inhibitor is active in the major types of sarcomas and that treatment using the CDK4/6 inhibitor palbociclib especially in combination with methionine restriction by methioninase or with a multikinase inhibitor is a promising strategy for sarcoma treatment in the clinic.